WallStreetZenWallStreetZen

NASDAQ: CTXR
Citius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for CTXR

Based on 1 analyst offering 12 month price targets for Citius Pharmaceuticals Inc.
Min Forecast
$4.00+419.48%
Avg Forecast
$4.00+419.48%
Max Forecast
$4.00+419.48%

Should I buy or sell CTXR stock?

Based on 1 analyst offering ratings for Citius Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTXR stock forecasts and price targets.

CTXR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-14

1 of 1

Forecast return on equity

Is CTXR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
24.42%

Forecast return on assets

Is CTXR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CTXR revenue forecast

What is CTXR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$185.2M
Avg 2 year Forecast
$225.1M
Avg 3 year Forecast
$461.6M

CTXR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTXR$0.77$4.00+419.48%Buy
NVCT$7.08$21.00+196.61%Buy
MDWD$13.25$28.00+111.32%Buy
CRBP$27.15$51.00+87.85%Buy
ANIX$3.77$12.00+218.30%Buy

Citius Pharmaceuticals Stock Forecast FAQ

Is Citius Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTXR) stock is to Buy CTXR stock.

Out of 1 analyst, 0 (0%) are recommending CTXR as a Strong Buy, 1 (100%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Pharmaceuticals stock.

What is CTXR's revenue growth forecast for 2024-2026?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Citius Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CTXR's revenue for 2024 to be $29,459,580,598, with the lowest CTXR revenue forecast at $29,459,580,598, and the highest CTXR revenue forecast at $29,459,580,598. On average, 2 Wall Street analysts forecast CTXR's revenue for 2025 to be $35,809,053,307, with the lowest CTXR revenue forecast at $19,298,196,935, and the highest CTXR revenue forecast at $52,319,909,680.

In 2026, CTXR is forecast to generate $73,441,332,805 in revenue, with the lowest revenue forecast at $73,441,332,805 and the highest revenue forecast at $73,441,332,805.

What is CTXR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CTXR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CTXR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTXR price target, the average CTXR price target is $4.00, with the highest CTXR stock price forecast at $4.00 and the lowest CTXR stock price forecast at $4.00.

The Wall Street analyst predicted that Citius Pharmaceuticals's share price could reach $4.00 by Feb 14, 2025. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 419.48% from the current CTXR share price of $0.77.

What is CTXR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CTXR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.